secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2023-08-30T23:59:59+00:00
Accession:  0000200406-23-000091
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ updates 2023 guidance post-Kenvue separation; raises sales & EPS outlook, cuts share count
--------------------------------------------------------------------------------

- Updated 2023 guidance: Reported Sales Growth 7.0%-8.0%, Adjusted EPS $10.00-$10.10 (12.5% growth at midpoint).
- Reduced share count by ~191M shares; partial-year benefit of ~73.5M shares adds $0.28 to EPS.
- Received $13.2B cash from Kenvue debt offering and IPO; retains 9.5% equity stake in Kenvue.
- Consumer Health now reported as discontinued ops; expects ~$20B gain in Q3 2023.
- Maintains quarterly dividend of $1.19/share; H1 2023 continuing ops sales $42.4B (+5.9% total).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/0000200406-23-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/jnj-20230830.htm
  HTML page:      https://secwatch.observer/filing/0000200406-23-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer